Natural approaches in metabolic syndrome management

doi:10.5114/aoms.2017.68717

. 2018 Mar;14(2):422-441.

doi: 10.5114/aoms.2017.68717. Epub 2017 Jul 19.

Natural approaches in metabolic syndrome management

Angelo Maria Patti^{1

2}, Khalid Al-Rasadi³, Rosaria Vincenza Giglio^{1

2}, Dragana Nikolic^{1

2}, Carlo Mannina¹, Giuseppa Castellino^{1

2}, Roberta Chianetta^{1

2}, Maciej Banach⁴, Arrigo F G Cicero⁵, Giuseppe Lippi⁶, Giuseppe Montalto¹, Manfredi Rizzo^{1

2}, Peter P Toth⁷

Affiliations

¹ Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Italy.
² EuroMediterranean Institute of Science and Technology, Italy.
³ Department of Clinical Biochemistry, Sultan Qaboos University, Muscat, Oman.
⁴ Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
⁵ Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
⁶ Section of Clinical Biochemistry, University of Verona, Verona, Italy.
⁷ CGH Medical Center, Sterling, Illinois; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

PMID: 29593818
PMCID: PMC5868676
DOI: 10.5114/aoms.2017.68717

Natural approaches in metabolic syndrome management

Angelo Maria Patti et al. Arch Med Sci. 2018 Mar.

. 2018 Mar;14(2):422-441.

doi: 10.5114/aoms.2017.68717. Epub 2017 Jul 19.

Authors

Affiliations

¹ Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Italy.
² EuroMediterranean Institute of Science and Technology, Italy.
³ Department of Clinical Biochemistry, Sultan Qaboos University, Muscat, Oman.
⁴ Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
⁵ Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
⁶ Section of Clinical Biochemistry, University of Verona, Verona, Italy.
⁷ CGH Medical Center, Sterling, Illinois; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

PMID: 29593818
PMCID: PMC5868676
DOI: 10.5114/aoms.2017.68717

Abstract

Metabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that raise the risk for heart disease and other health problems, such as diabetes mellitus and stroke. Treatment strategies include pharmacologic interventions and supplementary (or "alternative") treatments. Nutraceuticals are derived from food sources (isolated nutrients, dietary supplements and herbal products) that are purported to provide health benefits, in addition to providing basic nutritional value. Nutraceuticals are claimed to prevent chronic diseases, improve health, delay the aging process, increase life expectancy, and support the structure and function of the body. The study of the beneficial effects of nutraceuticals in patients with MetS, including product standardization, duration of supplementation and definition of optimal dosing, could help better define appropriate treatment. This review focuses on widely marketed nutraceuticals (namely polyphenols, omega-3 fatty acids, macroelements and vitamins) with clinically demonstrated effects on more than one component of MetS.

Keywords: cardiovascular risk; macroelements; metabolic syndrome; nutraceuticals; omega-3 fatty acids; polyphenols; vitamins.

PubMed Disclaimer

Cited by

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study.
Patti AM, Carruba G, Cicero AFG, Banach M, Nikolic D, Giglio RV, Terranova A, Soresi M, Giannitrapani L, Montalto G, Stoian AP, Banerjee Y, Rizvi AA, Toth PP, Rizzo M. Patti AM, et al. Metabolites. 2020 Oct 2;10(10):392. doi: 10.3390/metabo10100392. Metabolites. 2020. PMID: 33023123 Free PMC article.
Potential roles of Garcinia family as antimetabolic syndrome.
Kuswandi A, Tarawaan VM, Goenawan H, Muchtaridi M, Lesmana R. Kuswandi A, et al. J Adv Pharm Technol Res. 2022 Jan-Mar;13(1):1-6. doi: 10.4103/japtr.japtr_218_21. Epub 2022 Jan 21. J Adv Pharm Technol Res. 2022. PMID: 35223433 Free PMC article. Review.
Association of retinol binding protein-4, cystatin C, homocysteine and high-sensitivity C-reactive protein levels in patients with newly diagnosed type 2 diabetes mellitus.
Wang YS, Ye J, Yang X, Zhang GP, Cao YH, Zhang R, Dai W, Zhang Q. Wang YS, et al. Arch Med Sci. 2019 Sep;15(5):1203-1216. doi: 10.5114/aoms.2018.79565. Epub 2018 Nov 13. Arch Med Sci. 2019. PMID: 31572465 Free PMC article.
Omega-6 fatty acids and the risk of cardiovascular disease: insights from a systematic review and meta-analysis of randomized controlled trials and a Mendelian randomization study.
Mazidi M, Shekoohi N, Katsiki N, Banach M. Mazidi M, et al. Arch Med Sci. 2021 Apr 24;18(2):466-479. doi: 10.5114/aoms/136070. eCollection 2022. Arch Med Sci. 2021. PMID: 35316920 Free PMC article.
Transcriptome and metabolome changes induced by bitter melon (Momordica charantia)- intake in a high-fat diet induced obesity model.
Reed D, Kumar D, Kumar S, Raina K, Punia R, Kant R, Saba L, Cruickshank-Quinn C, Tabakoff B, Reisdorph N, Edwards MG, Wempe M, Agarwal C, Agarwal R. Reed D, et al. J Tradit Complement Med. 2021 Aug 19;12(3):287-301. doi: 10.1016/j.jtcme.2021.08.011. eCollection 2022 May. J Tradit Complement Med. 2021. PMID: 35493312 Free PMC article.

See all "Cited by" articles

References

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–97. - PubMed
1. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9:531–2. - PubMed
1. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–71. - PubMed
1. Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med. 2011;5:9–48. - PMC - PubMed
1. Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med. 2008;14:741–51. - PMC - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–97. - PubMed

[2] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–97. - PubMed

[3] Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9:531–2. - PubMed

[4] Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9:531–2. - PubMed

[5] Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–71. - PubMed

[6] Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–71. - PubMed

[7] Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med. 2011;5:9–48. - PMC - PubMed

[8] Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med. 2011;5:9–48. - PMC - PubMed

[9] Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med. 2008;14:741–51. - PMC - PubMed

[10] Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med. 2008;14:741–51. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Natural approaches in metabolic syndrome management

Affiliations

Natural approaches in metabolic syndrome management

Authors

Affiliations

Abstract

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources